A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Status:
Completed
Trial end date:
2019-05-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in
healthy participants and participants with AD. The study will also investigate how much
LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with
AD.
The study has two parts:
- Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to
17 weeks;
- Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about
317 days.